ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
IceCure Medical Ltd

IceCure Medical Ltd (ICCM)

0.6967
-0.0497
(-6.66%)
Closed July 23 4:00PM
0.6999
0.0032
(0.46%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.6999
Bid
0.6726
Ask
0.71
Volume
1,880,365
0.62 Day's Range 0.72
0.52 52 Week Range 1.57
Market Cap
Previous Close
0.7464
Open
0.72
Last Trade Time
Financial Volume
$ 1,275,904
VWAP
0.678541
Average Volume (3m)
203,356
Shares Outstanding
45,729,684
Dividend Yield
-
PE Ratio
-2.18
Earnings Per Share (EPS)
-0.32
Revenue
3.23M
Net Profit
-14.65M

About IceCure Medical Ltd

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surg... Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications. Show more

Sector
Medical Eq Rental & Leasing
Industry
Medical Eq Rental & Leasing
Headquarters
Cesaria, Isr
Founded
1970
IceCure Medical Ltd is listed in the Medical Eq Rental & Leasing sector of the NASDAQ with ticker ICCM. The last closing price for IceCure Medical was $0.75. Over the last year, IceCure Medical shares have traded in a share price range of $ 0.52 to $ 1.57.

IceCure Medical currently has 45,729,684 shares outstanding. The market capitalization of IceCure Medical is $34.13 million. IceCure Medical has a price to earnings ratio (PE ratio) of -2.18.

ICCM Latest News

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer...

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAESAREA, Israel, July 19, 2024 CAESAREA, Israel, July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd...

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer PR Newswire CAESAREA, Israel, July...

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel, July 1, 2024 CAESAREA, Israel, July...

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 PR Newswire CAESAREA, Israel, June 18, 2024 Recent insider...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0501-6.680.750.77790.62743180.75286CS
4-0.0201-2.791666666670.720.80.621328670.74306583CS
12-0.5001-41.6751.21.260.622033560.91505592CS
26-0.5701-44.88976377951.271.570.624486971.27846374CS
52-0.5301-43.09756097561.231.570.5213439391.08985707CS
156-11.1801-94.108585858611.8812.40.528206411.54377912CS
260-11.1801-94.108585858611.8812.40.528206411.54377912CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.54
(4.76%)
239M
SQQQProShares UltraPro Short QQQ
$ 8.09
(-4.37%)
183.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
SERVServe Robotics Inc
$ 8.73
(15.63%)
151.56M
NCPLNetcapital Inc
$ 0.1118
(7.50%)
124.37M

ICCM Discussion

View Posts
TechandBio TechandBio 16 hours ago


99% Cancer Free Breast Cancer Complete Response Cure Rate! after 10 years of follow up data on patients


Just went fishing for some shares this morning! Someone is tying to scare people out of their shares I just doubled up!
https://finance.yahoo.com/news/99-74-recurrence-free-rate-123000447.html

Demand for minimally invasive breast cancer treatment was overarching theme of the conference

In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recurrence free rate


Another independent study led by Professor Kawamoto found 0% breast cancer local recurrence in five-year follow up

ProSense® expected to gain further traction in Japan, as distribution partner Terumo Corporation plans to submit application to the Pharmaceuticals and Medical Devices Agency ("PMDA") for regulatory clearance for breast cancer in the first quarter of 2025.

Already approved in 15 countries.

Minimal invasive procedure that cures Breast Cancer independent studies around the world. Reviewed in a highly reputable medical journal.


$ICCM
👍️0
TechandBio TechandBio 2 days ago

Cures 97% of early breast cancer patients after 5 year follow up independent study.

Published in highly recognized medical journal.

92% Cure rate for Late stage Breast cancer patients with large Tumors



IceCure Medical's ProSense Cryoablation System



Dr. Belinda Barclay-White on Breast Tumor Cryoablation




FREEZING CANCER IN ITS TRACKS.


The Lee Family one of Asia Richest familes owns 52% of ICCM

The company has no outstanding warrants or debt

21 Million shares Floating.


Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally.


June 2024 Biz Presentation:
https://d1io3yog0oux5.cloudfront.net/_bff00726f3fc2e5c631f07f65bc0c3de/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM
👍️0
Paullee Paullee 2 days ago
shame no one cares
👍️0
TechandBio TechandBio 3 days ago
Cures 97% of early breast cancer patients after 5 year follow up independent study.

Published in highly recognized medical journal.

92% Cure rate for Late stage Breast cancer patients with large Tumors


FREEZING CANCER IN ITS TRACKS.


The Lee Family one of Asia Richest familes owns 52% of ICCM


Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally.



Study published in the peer reviewed journal Breast Cancer.

Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation

Strategic distribution partner of ProSense® in Japan, Terumo Corporation, expects to submit an application for regulatory clearance for breast cancer in the second half of 2024


https://ir.icecure-medical.com/news-events/press-releases/detail/126/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally
[color=red]


https://ir.icecure-medical.com/news-events/press-releases/detail/134/european-study-provides-more-evidence-supporting-icecures-prosense-is-safe-effective-cryoablation-treatment-for-metastatic-and-recurrent-breast-cancer

IceCure applications: Breast Cancer early and Late Stage, Kidney Lung, Liver Cancer, Pain, and Palliative Care, Fibroadenoma Kills bad fat cells (Obesity) application on tap!
https://www.icecure-medical.com/clinical-applications/

Recap IceCure no surgery in patient setting local anesthetic insurance companies have signed on. no radiation treatment! natural freezing that kills cancer tumors for early stage breast cancer with 97% success rate after 5 Years! This is expanding with late stage breast cancer wide array of oncology indications and large tumors. Lung, Kidney and Liver Cancer Approved in 15 countries and counting sales ramping up no debt or warrants.

Summer IceCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_bff00726f3fc2e5c631f07f65bc0c3de/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM[/color]
👍️0
it_happens it_happens 5 days ago
I read TechandBio's posts but usually don't reply. I view them as FYI. I do think we are on the cusp of a breakout soon here.
👍️0
TechandBio TechandBio 5 days ago
Cures Cancer

Early Breast Cancer after 5 year follow up 97% complete response rate for early stage breast cancer independent studies completed in multiple countries.
Highly acclaimed peered reviewed journal.
Late stage Breast cancer Data is 92% complete response rate.


ICE3 Trial - Positive Final Results

96.3% Free from local recurrence for patients treated with ProSense® Cryoablation.

100% Safe Procedure

No significant device-related adverse events or complications have been reported.

100% Doctor & Patient Satisfaction with ProSense® Procedure.

No scarring or change to the shape and size of the breast.


Billionaire owns 52% of the shares from one of the wealthiest families

Cryoablation minimally invasive no drugs needed to put the patient out only local anesthetic and the patient is home in two hours no stitches. No surgery no radiation This is very disruptive to the Cancer Space.

Approved in 15 countries.

I have been accumulating shares daily and will continue. Potential to break $10.00 and new highs. I bought PLSE at $1.30 and rode half my shares into the high teens!
Cryoablation is treating Kidney, Bone, Lung and Liver cancer and Palliative care interesting there could be an obesity angle as well as the Freezing temps kills tumors and bad fat cells.. Non Invasive Medicine is growing and as we go move forward in medicine these area of medicine will grow leaps and bounds.



Harvard Health Blog The skinny on freezing fat
https://www.health.harvard.edu/blog/the-skinny-on-freezing-fat-2020031218990#:~:text=Average%20reduction%20in%20fat%20ranges,depending%20on%20the%20desired%20results.


IceCure Medical's ProSense Cryoablation System


$ICCM
👍️0
investtemp investtemp 6 days ago
Ever get to feel you are talking (or praying) at a wall?
👍️0
TechandBio TechandBio 6 days ago
Cancer Cure= 97% success rate for killing cancerous tumors in early stage breast cancer patients! Complete Response rate after 5 year follow up data by independent studies conducted in multiple countries peer reviewed in highly acclaimed medical journals
Late Stage Breast cancer patients harder to treat with large tumors seeing similar data after 12 months.


100% patient and Dr Satisfaction.


Freezing and Killing Cancer in it;s Tracks IceCure Medical, enabling non-surgical
treatment of cancerous tumors.

IceCure website
https://www.icecure-medical.com/

Summer 2024 Biz Presentation:
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

Billionaire owns 52% of ICCM shares.

PLSE 1 Billion market cap was 50 million 2 years ago
ICCM 36 Million market cap

$ICCM
👍️0
TechandBio TechandBio 6 days ago
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for early and late stage breast cancer with tumors big and small with non complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and
local tumor control 5 year early breast cancer data success rate 97% late stage breast cancer with larger tumors nearly 93% success rate. This is the closest thing in breast cancer to a Cure and best in class results with local local anesthetic vs anesthesia in a surgery setting with 15-20% of lumpectomy patients need to go back for second surgery. This stock has a Billion dollar plus market cap potential by end of next year.=3000% upside if Pulse Bio Sciences did it from the low 1.00 range from 2 years ago and a 50 million dollar market cap a few years to a Billion dollar market cap today.
Both companies have large insider ownership Sales will ramp up for IceCure in the coming quarters.

$ICCM
👍️0
TechandBio TechandBio 7 days ago

IceCure Medical's ProSense Cryoablation System (next Frontier in cancer medicine)


IceCure Patient Testimonial - Georgette Rath


Approved in 15 countries and counting!

I know a Billion dollar plus company that is looking at Icecure for a potential acquisition. Could see a hostile take over at these discount prices sales will be ramping up especially next year. Perfect compliment to a biotech company that is in the minimally invasive cancer space or a blue chip biotech company. The device patent is valid till 2040. This is the closest cure to early breast cancer with 5 year follow up data 97% success rate roughly 93% on late stage breast cancer with data 12 months out Truly remarkable. Being used in the states today by patients who pay out of pocket FDA Clearance in USA will open up as insurance companies are already in place to cover it. Everybody wins 100% patient and Dr satisfaction. Treats a wide array of Cancers! No debt no warrants.

Very importan IceCure is fullyt backed by:
1.American Society of Breast Cancer Surgeons
2.Society of integrative Oncology
3.Society of interventional radiology

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class.
https://ir.icecure-medical.com/news-events/press-releases/detail/81/cryoablation-takes-center-stage-at-american-society-of-breast-surgeons-24th-annual-meeting

Icecure Biz presentation summer 2024
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf


$ICCM
👍️0
TechandBio TechandBio 1 week ago
Cancer Cure for early stage breast cancer 97% success rate with 5 year follow up independent data.
Approved in 15 countries
Late stage Breast cancer is showing best in class data with large tumor destruction with nearly 93% success rate for late stage breast cancer patients with 1 year follow up. The company is working on a wide array of cancer applications.

Oncology Indications
https://www.icecure-medical.com/clinical-applications/

Freezing Cancer in its Tracks IceCure Medical, enabling non-surgical treatment of cancerous tumors.

Billionaire Victor Lee owns 52% of the ICCM shares a man who help built Tencent into one the most successful tech companies in Asia. Comes from one of the richest families in Asia.
2024 June Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
👍️0
Flamingo Jack Flamingo Jack 1 week ago
IceCure Medical is proud to share the first renal #ProSense #cryoablation case performed at the Greek 251 Hellenic Air Force Hospital, with support of Dr. Robert Sachner who shared his vast experience of over 250 kidney lesion cryoablation procedures.
👍️0
TechandBio TechandBio 1 week ago
Dr. Belinda Barclay-White on Breast Tumor Cryoablation.
Cryoblation ice crystals Killing breast cancer tumors and dead fat. Ice3 Trial 5 year follow up killing 98% of small breast cancers better than surgery also has Data on later stage breast cancers with tumors twice the size as earlier studies with a 93% success rate for late stage Breast cancers.. .


$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
https://www.prnewswire.com/news-releases/icecure-medicals-breast-cryoablation-gains-prominence-in-the-us-as-society-of-interventional-oncology-annual-meeting-features-its-first-breast-cryoablation-master-class-302046623.html
[color=red]


Cryoablation Takes Center Stage at American Society of Breast Surgeons' 24th Annual Meeting.
IceCure's ProSense was the cryoablation system used in first-of-its-kind cryotherapy continuing medical education (CME) course.
High level of interest expressed in cryoablation from attending surgeons and from American Society of Breast Surgeons (ASBrS) leadership.
Plan presented for a proposed ASBrS Cryoablation trial during CME course.
https://ir.icecure-medical.com/news-events/press-releases/detail/81/cryoablation-takes-center-stage-at-american-society-of-breast-surgeons-24th-annual-meeting



Home Media and publications Media Archive SIR 2024 breast cancer


A minimally invasive technique that uses ice to freeze and destroy small, cancerous tumors has now been proven effective for breast cancer patients with large tumors, providing a new treatment path for those who are not candidates for surgery, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.
https://www.sirweb.org/media-and-pubs/media/news-release-archive/sir-2024-breast-cancer-032024/

Choose the Power of Liquid Nitrogen Cryoablation for a Wide Range of Clinical Applications[/color]
https://www.icecure-medical.com/clinical-applications/
June 2024 ICeCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
Organizations supporting IceCure in the USA:
1.The American Society of Breast Surgeons | ASBRS
2.Society for Integrative Oncology
3.Society of Interventional Radiology

$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
Victor Li, head of one of Hong Kong’s oldest business empires And from one of the richest families in China, has been busy forging partnerships with a slew of mainland Chinese technology companies including (Tencent 3.60 trillion Hong kong dollars) to modernize CK Group including deals after taking over the conglomerate earlier this year.


$ICCM
Victor Li owns over 52% of ICCM
$PLSE was about 1.30 a few years ago to a high of $17.00 this year and their majority owned by Bob Duggan and the company went from a 50 Million market cap to over a billion dollar market cap in no time.
ICCM has massive upside When it breaks $2.00-$10.00+ will happen its all in the charts!.
Very honored to have Vic Li, our leading shareholder and his associate, Yankor Huang, visit the IceCure offices today and see our #LN2 #cryoablation technology in action. Thank you for your continued belief and support in us!
Victor Lee the Business tycoon has been an active major shareholder for 9 years.
https://www.facebook.com/IceCureMedical/posts/2448349238625488/
👍️0
Paullee Paullee 2 weeks ago
The Evolving Role of Cryosurgery in Breast Cancer Management: A Comprehensive Review - PMC


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486449/
👍️ 1
TechandBio TechandBio 2 weeks ago
Starting to build core positions in small cap hidden gems this is one of them. Once it breaks $2.00 area $10.00+ is in play.
ProSense™ cryoablation system generates ultra-cold temperatures quickly to create large lethal zones for maximum tumor destruction.


Step 1. The cryoprobe is inserted into the tumor at a small incision site.

Step 2 .The tumor is surrounded by an ice ball. The extreme cold kills the tumor tissue.

Step 3. The cryoprobe is removed and a Steri-Strip is applied, requiring no stitches. (local anesthetic) patient is back home in a couple of hours after procedure.

Breast Cancer – U.S. Healthcare Economics &
Reimbursement
Healthcare Economics: Cryoablation costs less than standard-of-care lumpectomy and
further reduces costs by reducing risk of re-excision as compared to lumpectomy.


$ICCM
👍️0
it_happens it_happens 2 weeks ago
This is great news for women worldwide. Hope this procedure is 100% successful. This would be such a great medical advancement. In the US, if a woman discovers breast cancer, the best outcome is most likely a partial mastectomy and successful chemotherapy. Discovering breast cancer early requires timely and state of the art testing. The lump test discovers cancer that might require full mastectomy. Women should test regularly.
👍️ 1
TechandBio TechandBio 2 weeks ago
Bob Duggan thinking about buying IceCure? Fits his ethos to a tee. He's worth about 6 Billion dollars.
The trend of minimal/non invasive technologies not needing surgery is growing substantially from patients to doctors and insurance companies and rain makers like Duggan and many others. The new paradigm of medicine is starting to change at an accelerated pace. ICCM exceptional data now showing treatment for later stage breast cancers with bigger tumors is game changing for IceCure. And displaying remarkable data results for Lung, Kidney, Bone Cancer. Taking a local anesthetic being able to go home in a few hours with no scaring most important the results of IceCure Patients and Doctors are nearly 100% satisfied. Killing cancer by Freezing it in it's tracks with 5 year follow up studies in early breast cancer patients and highly showcased in a highly acclaimed peer reviewed publication approved in 15 countries and the list is growing.
$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
Independent Studies Confirm ICE3 Results
In women with early-stage breast cancer who
declined surgery.
Study conducted by Principal Investigator Lucía Graña-López,
MD, PhD, a radiologist who specializes in breast and women's
imaging, Head of the Breast Unit at University Hospital Lucus
Augusti, Spain—presented at European Society of Breast Imaging Annual Scientific Meeting 2023 96.8% Success rate.

93.4% - 96.8%
Tumor reduction rate
In women deemed inoperable for breast cancer.

Breast Cancer – U.S. Healthcare Economics &
Reimbursement
Healthcare Economics: Cryoablation costs less than standard-of-care lumpectomy and
further reduces costs by reducing risk of re-excision as compared to lumpectomy1
Reimbursement:
Demonstrating its leadership in cryoablation, IceCure is the first company to apply for and
receive Medicare coverage for breast cancer cryoablation through the Centers for Medicare & Medicaid
Services (CMS)
CMS assigned CPT Category III 2 Breast/Lymphatic Surgery and Related Procedures
Priced for coverage by the CMS at approximately $3,400 for the facility fee alone
Additional coverage, including payment for the physician, is expected upon establishment of the
permanent CPT Category I 2 code
Patient demand drives reimbursement.

Large insider buys a few weeks ago 57% of the stock is Insider Owned.

21 Million shares Floating

No warrants no debt no history of reverse splits.

$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
Killing Cancer Tumors by Freezing them new paradigm in medicine.

Growing number of global distribution agreements. More to come!

Insurance Reimbursement: CPT III for breast cancer cryoablation facility fee established.

51 IP Patents

Excellent patient & physician feedback.

Peer Reviewed Journal completed.

Data displaying next level treatment for early and now late stage cancer patients with larger tumors.


Independent clinical trials are investigating the use of cryoablation in the treatment of endometriosis; a condition that impacts over 6.5 million women in the U.S.

Best in Class data displayed in Breast Cancer, Lung Cancer, Bone Cancer, Kidney Cancer.

Growing cancer burden Increasing demand for non/minimal-invasive solutions Push for reduced cost of care by insurers & payers.


June 2024 IceCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM
👍️0
Flamingo Jack Flamingo Jack 2 weeks ago
Presently waiting on FDA approval for marketing the prosense device for breast cancer in the US. I think early to mid 2025 will be where a ton of good news will flow in. In the meantime we should await quarterly results and accumulate.
👍️0
TechandBio TechandBio 2 weeks ago
This higher risk patient population included patients with metastatic disease and tumors of up to 4 centimeters in diameter, as compared to our ICE3 study population with early-stage disease and tumors smaller than 2 centimeters in diameter, indicating a very different recurrence rate. Importantly, it further informs and supports the use cases of ProSense® across a broader range of breast cancer diagnoses, from newly diagnosed early-stage to metastatic and recurrent disease,"
92% non recurrence rate for higher risk later stage breast cancer with tumors twice the size 4 centimeters is remarkable. Someone is trying to steal shares from the low brow. 97% tumor free for early stage breast cancer with tumors 2 centimeters in diameter with 5 years of FOLLOW UP DATA.
$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
Prior Studies where for early stage breast cancer now there is incredible data for dealing with later stage and higher risk breast cancer patients. This is big news it moves when it moves I will keep adding at these levels!
👍️0
TechandBio TechandBio 2 weeks ago
Now have superior data on higher risk breast cancer patients!
Professor Vogl commented, "Liquid Nitrogen-based cryoablation was found to be a safe local treatment for breast cancer, with a low complication rate—in fact, none were observed in the study. We experienced a very high complete ablation rate of 100%.

Treating higher risk breast cancer patients makes ICCM platform more dynamic plus treating Lung, Kidney and Bone cancer patients with cryoblast. Giving options for patients who don't want surgery or radiation treatment with these incredible data points and 100% patient and Dr satisfaction using ICCM technology IceCure will be valued closer to PLSE market cap which is a Billion dollars.[
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and local tumor control.

$ICCM
👍️0
it_happens it_happens 2 weeks ago
Not sure why this isn't trading higher. This is much-needed technology and treatment.
👍️0
Paullee Paullee 2 weeks ago
even more good news



European Study Provides More Evidence Supporting IceCure’s ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer



? Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and local tumor control
? 8.9% recurrence rate in population of 45 patients who had previously received various therapies before cryoablation including surgery, radiation therapy, or chemotherapy with tumor sizes of up to 4 centimeters in diameter. Of those patients, 11 had recurrent tumors and 21 had metastatic disease
? The higher-risk population in this European study contrasts with the early-stage breast cancer patient subjects in the U.S. ICE3 study


CAESAREA, Israel, July 9, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study evaluating its flagship cryoablation system ProSense® titled: “CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience” in Cancers, a leading peer-reviewed oncology journal. The study, led by Principal Investigator Professor Thomas J. Vogl, was conducted at the Institute of Radiology and Nuclear Medicine, University Hospital Frankfurt, at Goethe University, Germany.



Professor Vogl commented, “Liquid Nitrogen-based cryoablation was found to be a safe local treatment for breast cancer, with a low complication rate—in fact, none were observed in the study. We experienced a very high complete ablation rate of 100%. Overall survival, progression free survival and local tumor control were all good, especially given the very heterogenous patient population. The fact that this is a minimally invasive procedure that can be performed on an outpatient basis with excellent cosmetic results are clear advantages. We look forward to further evaluations of cryoablation especially in comparison to other treatment modalities for early, recurrent, and metastatic breast cancer.”



“While this study’s patient population is very different from our U.S. based ICE3 study and the target indication for which we have filed for regulatory approval in the U.S., the results of the study are highly valuable for ProSense® users in Europe where our system is approved for general breast cancer treatment. This higher risk patient population included patients with metastatic disease and tumors of up to 4 centimeters in diameter, as compared to our ICE3 study population with early-stage disease and tumors smaller than 2 centimeters in diameter, indicating a very different recurrence rate. Importantly, it further informs and supports the use cases of ProSense® across a broader range of breast cancer diagnoses, from newly diagnosed early-stage to metastatic and recurrent disease,” stated IceCure CEO Eyal Shamir. “We thank Dr. Vogl, his team, and University Hospital Frankfurt for their initiative in conducting this study and expanding the body of knowledge for the cryoablation of breast cancer.”



This independent study, which received no financial support from IceCure, retrospectively evaluated the efficacy and safety of liquid-nitrogen based CT-guided cryoablation with ProSense®. Patients were treated in out-patient settings with curative intention for non-metastatic patients, while patients with metastases were treated to achieve local tumor control. The patient population (n=45, with 56 tumors) with a mean age of 55.6 ± 12.5 years (range, 31.3–86.0 years) was very heterogeneous and different from IceCure’s ICE3 study population and included 11 patients with recurrent tumors and 21 patients with metastatic disease. Patients were observed at three, six, nine, and 12 months, respectively, and after the first year were followed up biannually. There were four cases of local tumor progression, representing a rate of 8.9%. There were no complications observed in any of the 56 ablations and initial complete ablation was achieved in 100% of cases.
👍️0
TechandBio TechandBio 2 weeks ago
Gets Past $2.00+ then $10.00+ in the play Charts says it all.
Killing all kinds of cancers with follow up Data on patients for 5 years and counting.
This stock should be trading 10-30x the current market cap more inline with Pulse Bio Sciences a Billion dollar market cap that has no revenue and is doing just cosmetic dermatology skin treatments.That stock was trading around a dollar a few years ago.
IceCure will make some people hyper wealthy.
$ICCM
👍️0
TechandBio TechandBio 2 weeks ago


“Cryoablation is a procedure that we know is safe, efficacious, cost effective and cosmetically superior to surgical removal. IceCure has improved upon the technology and developed a system optimized for breast fibroadenoma. My patients have been very happy with the short, painless procedure, and the ability to return to normal activity immediately.”

Andrew Kenler, MD, FACS
👍️ 1
TechandBio TechandBio 2 weeks ago
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally
https://www.prnewswire.com/il/news-releases/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally-302137926.html
$ICCM
👍️0
TechandBio TechandBio 2 weeks ago
IceCure non invasive treatment freezing cancers compared to surgery including breast cancer, Lung cancer, Kidney cancer Fibroadenoma and Palliative care.
I was in Pulse around the $1.75 range and believe IceCure has tremendous growth approved in 15 countries. FDA approval Q4 or early Q1 5 year follow up Data with 100% patient and doctor approval ratings. Over 55% insider ownership. No warrants or debt. 96% non recurrence rate for early stage malignant breast cancer.

RSI 32 Oversold.

June 2024 IceCure Business Presentation.
https://d1io3yog0oux5.cloudfront.net/_1427e4e7e9d44c0c61187db90d33f6f4/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM
👍️0
Paullee Paullee 3 weeks ago
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes



CAESAREA, Israel, July 1, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received marketing authorization from the United States Food and Drug Administration (the “FDA”) for its next-generation single probe cryoablation system, the XSense™ Cryoablation System with CryoProbes.



“This latest FDA regulatory clearance further validates the safety and efficacy of our platform cryoablation technology,” commented Eyal Shamir, IceCure’s Chief Executive Officer. “The next-generation XSense™ system is cleared for the same indications as our flagship ProSense® system and we believe it has future potential to address other indications in the U.S. for significant indications with unmet needs. Through our innovation, IceCure is a global leader in liquid nitrogen-based cryoablation systems that offer a new minimally invasive treatment with benefits for patients, doctors and payors alike.”



XSense™ and its cryoprobes are cleared for all of the indications for which ProSense® has already received the requisite FDA clearance, including general minimally invasive cryoablation in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT, gynecology, oncology, proctology and urology. The system is designed to destroy tissue by the application of extreme cold temperatures, including fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions and warts.



About IceCure’s Cryoablation Systems



IceCure’s platform technology, including the ProSense® Cryoablation System and XSense™ Cryoablation System and CryoProbes, provides a minimally invasive treatment option to destroy tumors by freezing them. The systems uniquely harness the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.



IceCure’s cryoablation systems enhance patient and provider value by accelerating recovery, reducing pain, surgical risks and complications. With easy, transportable design and liquid nitrogen utilization, ProSense® and XSense™ open the door to fast and convenient office-based procedure for breast tumors.
👍️0
Paullee Paullee 2 months ago
Guess Mr Market wasn't happy with the timing

FDA to Convene Advisory Panel for Review of IceCure’s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan



? Demonstrates public health importance of assessing ProSense®’s potential to offer optimal treatment that benefits women with early-stage breast cancer
? Patients, patient advocacy groups, doctors, and the general public will be welcome to participate and comment in the open public hearing
? IceCure welcomes a transparent public forum to share ICE3 study results and show how ProSense® cryoablation could potentially offer a minimally invasive alternative treatment to women diagnosed with early-stage breast cancer estimated at 65,000 in the U.S. annually
? ProSense® is already approved for the treatment of early-stage breast cancer in numerous European countries, as well as Brazil, India, and China


CAESAREA, Israel, June 4, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug Administration (“FDA”) will convene a Medical Device Advisory Committee for a panel meeting (the “Advisory Panel”) to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® to help the FDA make a sound decision.



“We believe the opportunity to have a public, transparent, and open forum about this important women’s health issue, led by outside, independent experts including physicians and researchers, will be highly beneficial to all stakeholders,” stated IceCure’s CEO, Eyal Shamir. “We applaud the FDA’s decision to convene the Advisory Panel and for acknowledging the public health importance of being able to offer a minimally invasive alternative to lumpectomy. The ICE3 data for ProSense®, which has been consistently positive throughout IceCure’s ICE3 study, will be shared with the Advisory Panel, highlighting its clinical and economic benefits and why women who have undergone a ProSense® cryoablation procedure have reported a 100% satisfaction rate. As we continue to engage with the FDA leading up to the Advisory Panel, we believe increased awareness of ProSense® as a result of the Advisory Panel may enable our U.S. commercial team to further support our commercial efforts upon potential regulatory approval in the U.S.”



The Advisory Panel is expected to convene in the fourth quarter of 2024, with an FDA decision on whether to approve ProSense® expected by early 2025. The FDA is expected to provide the exact date for the Advisory Panel in the coming weeks, which the Company will also make known to its shareholders. The FDA generally makes Advisory Panel meeting materials and the live webcast link available to the public no later than two business days before any meeting. The Advisory Panel will review the vast body of data available on ProSense® as a treatment for early-stage breast cancer, including results from the ICE3 study, the largest controlled multicenter clinical trial ever performed for liquid nitrogen-based cryoablation of early-stage malignant breast tumors. Per the analysis, at the 5-year follow-up evaluation, 96.3% of the subgroup of patients treated with ProSense® cryoablation, followed by hormone therapy, were estimated to be free from local recurrence. 100% patient and physician satisfaction was reported.



As part of its De Novo Classification Request for Marketing Authorization, IceCure submitted data, including its final ICE3 study results, to the FDA, as part of its request for clearance for ProSense® for the indication of treating patients with early stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy.
👍️ 1
Boing x 2 Boing x 2 2 months ago
Talk about timing,

"https://ih.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/93980503/fda-to-convene-advisory-panel-for-review-of-icecur"

Boing X 2
👍️ 1
Boing x 2 Boing x 2 2 months ago
I was able to get my stink bid at 1.03 a share for 5k shares filled today. Took 3 days of waiting;

For me this was a no brainer. I go back for what is hopefully my last 3 month cat scan for my lung tumor. Then if all is ok twice a year and then once every. year. Had been watching the spot for two years and jumped on it when it changed.

Believe me when I say the radiation had a lot of side effect that lasted for a long time. I wish I could have gone this route but it was next to the pulmonary artery and I think that would have presented a problem for me. The little bugger tried to avoid the raidiation and moved enough that the oncologist had to completely re calculate the radiation location.

Best of luck to all on a quick FDA approval.

Boing X 2
👍️0
Flamingo Jack Flamingo Jack 2 months ago
Waiting on FDA response. Patience pays.
👍️0
Paullee Paullee 3 months ago
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
10:30 am ET April 30, 2024 (PR Newswire) Print
USA News Group Commentary

USA News Group - An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN),and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Following a Fast Track Designation by the FDA in late 2022 for Oncolytics Biotech Inc.'s (NASDAQ: ONCY) (TSX: ONC) drug candidate, pelareorep, for pancreatic cancer treatment, the company is now gaining traction towards another pivotal FDA engagement, this time focusing on breast cancer. Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.

"A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics. "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer. Our position is strengthened by encouraging data from two randomized studies (BRACELET-1 and IND-213) and the AWARE-1 study, paving the way for the next phase of pelareorep's development and registration."

Dr. Coffey has shared that Oncolytics' continuous interactions with clinical collaborators and partners have been instrumental in crafting a detailed and persuasive briefing document. The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer. This meeting is crucial for advancing this promising therapy toward patient use. With expected survival data from its BRACELET-1 study and constructive dialogues with the FDA, Oncolytics is optimistic that 2024 will be a landmark year for the company and its stakeholders.

"The data from the randomized BRACELET-1 trial showcased compelling results for the pelareorep/paclitaxel combination therapy in HR+/HER2- metastatic breast cancer patients, with a nearly tripled confirmed response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. "Importantly, these data support the statistically significant near doubling of median overall survival in another randomized phase 2 study, IND-213, which also evaluated pelareorep and paclitaxel in HR+/HER2- metastatic breast cancer patients."

Also seeking the FDA's attention, Israel-based IceCure Medical Ltd (NASDAQ: ICCM) recently reported its final ICE3 breast cancer cryoablation trial results with 100% patient and physician satisfaction and 96.3% recurrence-free rate for its ProSense(R) System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal.

With this new data in hand, IceCure has submitted final data to the FDA, requesting marketing authorization for ProSense(R) for the indication of treating patients with early-stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. ProSense(R) has already received FDA Breakthrough Designation and is cleared for use in the US for several other indications, including treating benign tumors of the breast, and tumors in the kidney and liver.

"We believe ICE3 is a ground-breaking study and are excited to report that the efficacy data of our minimally invasive ProSense(R) cryoablation procedure show similar outcomes in recurrence compared to more invasive breast surgery, the current standard of care for early-stage breast cancer," said Eyal Shamir, CEO of IceCure. "Initial reimbursement codes are already in place and our U.S. marketing and commercial team is ready, as we await the FDA's response. Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption pending FDA granting the DeNovo Classification Request for Marketing Approval."

A new clinical trial was announced by Atossa Therapeutics, Inc. (NASDAQ: ATOS)to evaluate the company's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO(R)), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Set to enroll approximately 20 newly diagnosed women, the new study arm will have participants receiving 40mg (Z)-endoxifen once daily in combination with 150mg abemaciclib twice daily for a total of 24 weeks prior to surgery.

"Endocrine therapy in combination with CDK 4/6 inhibition is a widely used treatment for patients with advanced-stage ER+ breast cancer and as an adjuvant therapy for node positive, hormone positive early-stage disease, found at the time of surgical resection," said Dr. Laura Esserman, director of the University of California San Francisco Breast Care Center and founder of Quantum Leap Healthcare Collaborative. "Women with high clinical stage but less proliferative tumors (molecularly low risk or those with late recurrence risk) are challenging to treat. Late recurrence is high regardless of either endocrine or chemotherapy. Thus, we are looking for new combined treatments, which can be used in the pre-surgery (neoadjuvant) setting. We look forward to learning more about the potential of (Z)-endoxifen in combination with abemaciclib in the neoadjuvant setting in the I-SPY TRIAL."

Vepdegestrant (ARV-471) is another treatment that recently received FDA Fast Track Designation, which is a novel oral PROteolysis Targeting Chimera (PROTAC(R)) ER degrader that is being jointly developed by Arvinas, Inc. (NASDAQ: ARVN),and Pfizer Inc. (NYSE: PFE) (NEO: PFE). The ongoing Phase 3 VERITAC-2 clinical trial is evaluating vepdegestrant or fulvestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer who have been previously treated with an endocrine-based therapy.

"The receipt of Fast Track designation reinforces the potential of vepdegestrant to provide an important new therapeutic option for people with ER+/HER2- breast cancer whose disease has progressed," said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer. "We are proud to continue our legacy of developing innovative treatment options for people impacted by metastatic breast cancer and look forward to working with the FDA as we advance our development program for vepdegestrant."

Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
👍️ 1
User-840664 User-840664 3 months ago
This stock is one that is worth watching.
After the next financing, I might be a buyer... Around $0.77
👍️0
DK11 DK11 3 months ago
Not so sure about Fake News.
👍️0
cooltrey247 cooltrey247 3 months ago
Fake news
👍️0
Awl416 Awl416 3 months ago
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
👍️0
frankyahoo frankyahoo 4 months ago
FDA Regulatory filing submitted PR this morning.
👍️0
glenn1919 glenn1919 4 months ago
ICCM......................................https://stockcharts.com/h-sc/ui?s=ICCM&p=W&b=5&g=0&id=p86431144783
👍️0
Protocola Protocola 4 months ago
Goooooo!!!!!!!!!!!
$ICCM
👍️0
DollarDan DollarDan 5 months ago
I am not sure why this stock is going down on what seems like fantastic news. My guess is people have it on auto pilot to sell at a certain price. Hope it rockets today.
👍️0
Paullee Paullee 5 months ago
WOW!!!!
👍️0
Goofy R Goofy R 6 months ago
BOOOOOOOOM!! Wish I Had More Shares!

Wait until this gets full FDA approval... this could be a 100X Bagger!
👍️0
Boing x 2 Boing x 2 6 months ago
New news,

"https://finance.yahoo.com/news/icecure-medicals-prosense-featured-indian-130000869.html"

"https://finance.yahoo.com/news/icecure-medicals-breast-cryoablation-gains-130000647.html"

Boing X 2
👍️0
makinezmoney makinezmoney 7 months ago
$ICCM: BOOOooommmmmmmmmmmmmmmmmm.......... now 1.50

She gone................. just like that.

Nice rise


GO $ICCM
👍️0

Your Recent History

Delayed Upgrade Clock